Europe has followed the U.S. in approving a vaccine for all types of hepatitis B surface antigen from VBI Vaccines. The drug is the only differentiated adult hepatitis B vaccine approved for use worldwide. Registration of the drug in Russia is in the final stages and Pharmsintez is the exclusive distributor. The drug is expected to appear on the Russian market by the end of the year.